메뉴 건너뛰기




Volumn 10, Issue 11, 2011, Pages 1609-1620

Vaccination of travelers: How far have we come and where are we going?

Author keywords

cholera vaccine; dengue vaccine; hepatitis A and B; influenza vaccine; Japanese encephalitis; malaria vaccine; meningococcal vaccine; rabies vaccine; tick borne encephalitis vaccine; travel vaccines; yellow fever vaccine

Indexed keywords

CHIMERIVAX DENGUE; CHOLERA VACCINE; DENGUE VACCINE; DIPLOID CELL VACCINE; ENCEVIR; FSME IMMUN; HEPATITIS A ANTIBODY; HEPATITIS A HEPATITIS B VACCINE; HEPATITIS A VACCINE; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; HEPATYRIX; INFLUENZA VACCINE; JAPANESE ENCEPHALITIS VACCINE; MALARIA VACCINE; MENINGOCOCCUS VACCINE; MORC VAX; MUTACOL; RABIES IMMUNOGLOBULIN; RABIES VACCINE; SHANCHOL; TBE MOSCOW; TICK BORNE ENCEPHALITIS VACCINE; UNCLASSIFIED DRUG; VIATIM; VIVAXIM; YELLOW FEVER VACCINE;

EID: 80455158298     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.11.138     Document Type: Review
Times cited : (7)

References (117)
  • 1
    • 44249106822 scopus 로고    scopus 로고
    • Health risks among travelers - Need for regular updates
    • DOI 10.1111/j.1708-8305.2008.00198.x
    • Steffen R, Amitirigala I, Mütsch M. Health risks among travellers - need for regular updates. J. Travel Med. 15(3), 145-146 (2008). (Pubitemid 351724956)
    • (2008) Journal of Travel Medicine , vol.15 , Issue.3 , pp. 145-146
    • Steffen, R.1    Amitirigala, I.2    Mutsch, M.3
  • 2
    • 0027174940 scopus 로고
    • Hepatitis A and hepatitis B: Risks compared with other vaccine preventable diseases and immunization recommendations
    • DOI 10.1016/0264-410X(93)90221-I
    • Steffen R. Hepatitis A and B: risks compared with other vaccine-preventable diseases and immunization recommendations. Vaccine 11, 518-520 (1993). (Pubitemid 23130855)
    • (1993) Vaccine , vol.11 , Issue.5 , pp. 518-520
    • Steffen, R.1
  • 3
    • 70449715600 scopus 로고    scopus 로고
    • Hepatitis B immunization coverage and risk behaviour among danish travellers: Are immunization strategies based on single journey itineraries rational
    • Nielsen US, Petersen E, Larsen CS. Hepatitis B immunization coverage and risk behaviour among Danish travellers: are immunization strategies based on single journey itineraries rational? J. Infect. 59(5), 353-359 (2009).
    • (2009) J. Infect. , vol.59 , Issue.5 , pp. 353-359
    • Nielsen, U.S.1    Petersen, E.2    Larsen, C.S.3
  • 4
    • 33646715581 scopus 로고    scopus 로고
    • Prevention of hepatitis A through active or passive immunization: Recommendations of the advisory committee on immunization practices ACIP
    • CDC RR-7
    • CDC. Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm. Rep. 55(RR-7), 1-23 (2006).
    • (2006) MMWR Recomm. Rep. , vol.55 , pp. 1-23
  • 7
    • 35348976213 scopus 로고    scopus 로고
    • Update: Prevention of hepatitis A after exposure to hepatitis A virus and in international travelers updated recommendations of the advisory committee on immunization practices ACIP
    • CDC.
    • CDC. Update: prevention of hepatitis A after exposure to hepatitis A virus and in international travelers. Updated recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb. Mortal. Wkly Rep. 56(41), 1080-1084 (2007).
    • (2007) MMWR Morb. Mortal. Wkly Rep. , vol.56 , Issue.41 , pp. 1080-1084
  • 8
    • 67649297326 scopus 로고    scopus 로고
    • Surveillance for acute viral hepatitis - United States 2007
    • CDC.SS03
    • CDC. Surveillance for acute viral hepatitis - United States, 2007. MMWR Surveill. Summ. 58(SS03), 1-27 (2009).
    • (2009) MMWR Surveill. Summ. , Issue.58 , pp. 1-27
  • 9
    • 52649120886 scopus 로고    scopus 로고
    • Recommendations for identification and public health management of persons with chronic hepatitis B virus infection
    • RR-8
    • Weinbaum CM, Williams I, Mast EE et al. Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. MMWR Recomm. Rep. 57(RR-8), 1-28 (2008).
    • (2008) MMWR Recomm. Rep. , vol.57 , pp. 1-28
    • Weinbaum, C.M.1    Williams, I.2    Mast, E.E.3
  • 10
    • 39049191182 scopus 로고    scopus 로고
    • A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: Recommendations of the advisory committee on immunization practices ACIP part II: Immunization of adults
    • RR16
    • Mast EE, Weinbaum CM, Fiore AE et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP). Part II: Immunization of adults. MMWR Recomm. Rep. 55(RR16), 1-40 (2006).
    • (2006) MMWR Recomm. Rep. , vol.55 , pp. 1-40
    • Mast, E.E.1    Weinbaum, C.M.2    Fiore, A.E.3
  • 11
    • 79551617591 scopus 로고    scopus 로고
    • Recommended adult immunization schedule - United States 2011
    • CDC
    • CDC. Recommended adult immunization schedule - United States, 2011. MMWR Morb. Mortal. Wkly 60(4), 1-4 (2011).
    • (2011) MMWR Morb. Mortal. Wkly , vol.60 , Issue.4 , pp. 1-4
  • 12
    • 72849153267 scopus 로고    scopus 로고
    • Antibody levels and protection after hepatitis B vaccine: Results of a 22-year follow-up study and response to a booster dose
    • McMahon BJ, Dentinger CM, Bruden D et al. Antibody levels and protection after hepatitis B vaccine: results of a 22-year follow-up study and response to a booster dose. J. Infect. Dis. 200(9), 1390-1396 (2009).
    • (2009) J. Infect. Dis. , vol.200 , Issue.9 , pp. 1390-1396
    • McMahon, B.J.1    Dentinger, C.M.2    Bruden, D.3
  • 13
    • 0343090826 scopus 로고    scopus 로고
    • Can monovalent hepatitis A and B vaccines be replaced by a combined hepatitis A/B vaccine during the primary immunization course?
    • DOI 10.1016/S0264-410X(00)00166-3, PII S0264410X00001663
    • Kallinowski B, Knoll A, Lindner E et al. Can monovalent hepatitis A and B vaccines be replaced by a combined hepatitis A/B vaccine during the primary immunization course? Vaccine 19, 16-22 (2001). (Pubitemid 30618950)
    • (2000) Vaccine , vol.19 , Issue.1 , pp. 16-22
    • Kallinowski, B.1    Knoll, A.2    Lindner, E.3    Sanger, R.4    Stremmel, W.5    Vollmar, J.6    Zieger, B.7    Jilg, W.8
  • 15
    • 0035929698 scopus 로고    scopus 로고
    • Notice to readers: FDA approval for a combined hepatitis A and B vaccine
    • CDC
    • CDC. Notice to readers: FDA approval for a combined hepatitis A and B vaccine. MMWR Morb. Mortal. Wkly Rep. 50, 806-807 (2001).
    • (2001) MMWR Morb. Mortal. Wkly Rep. , vol.50 , pp. 806-807
  • 16
    • 0034897845 scopus 로고    scopus 로고
    • Long-term persistence of antibodies induced by vaccination and safety follow-up with the first combined vaccine against hepatitis A and B in children and adults
    • Van Damme P, Leroux-Roels G, Law B et al. Long-term persistence of antibodies induced by vaccination and safety follow-up, with the first combined vaccine against hepatitis A and B in children and adults. J. Med. Virol. 65(1), 6-13 (2001).
    • (2001) J. Med. Virol. , vol.65 , Issue.1 , pp. 6-13
    • Van Damme, P.1    Leroux-Roels, G.2    Law, B.3
  • 17
    • 34247131249 scopus 로고    scopus 로고
    • Ten-year antibody persistence induced by hepatitis A and B vaccine (Twinrix™) in adults
    • DOI 10.1016/j.tmaid.2006.07.003, PII S1477893906000925
    • Van Herck K, Leroux-Roels G, Van Damme P, Srinivasa K, Hoet B. Ten-year antibody persistence induced by hepatitis A and B vaccine (Twinrix) in adults. Travel Med. Infect. Dis. 5(3), 171-175 (2007). (Pubitemid 46585955)
    • (2007) Travel Medicine and Infectious Disease , vol.5 , Issue.3 , pp. 171-175
    • Van Herck, K.1    Leroux-Roels, G.2    Van Damme, P.3    Srinivasa, K.4    Hoet, B.5
  • 18
    • 77955509544 scopus 로고    scopus 로고
    • Comparison of long-term 10 years immunogenicity of two-and three-dose regimens of a combined hepatitis A and B vaccine in adolescents
    • Beran J, Kervyn D, Wertzova V et al. Comparison of long-term (10 years) immunogenicity of two- and three-dose regimens of a combined hepatitis A and B vaccine in adolescents. Vaccine 28(37), 5993-5997 (2010).
    • (2010) Vaccine , vol.28 , Issue.37 , pp. 5993-5997
    • Beran, J.1    Kervyn, D.2    Wertzova, V.3
  • 19
    • 33846330603 scopus 로고    scopus 로고
    • Rapid and sustained immune response against hepatitis A and B achieved with combined vaccine using an accelerated administration schedule
    • DOI 10.1111/j.1708-8305.2006.00106.x
    • Connor BA, Blatter MM, Beran J, Zou B, Trofa AF. Rapid and sustained immune response against hepatitis A and B achieved with combined vaccine using an accelerated administration schedule. J. Travel Med. 14(1), 9-15 (2007). (Pubitemid 46114981)
    • (2007) Journal of Travel Medicine , vol.14 , Issue.1 , pp. 9-15
    • Connor, B.A.1    Blatter, M.M.2    Beran, J.3    Zou, B.4    Trofa, A.F.5
  • 20
    • 15244361739 scopus 로고    scopus 로고
    • A two-dose schedule for combined hepatitis A and B vaccination in children aged 6-15 years
    • DOI 10.1016/j.vaccine.2004.11.059
    • Kurugöl Z, Mutlubas F, Ozacar T. A two-dose schedule for combined hepatitis A and B vaccination in children aged 6-15 years. Vaccine 23(22), 2876-2880 (2005). (Pubitemid 40386489)
    • (2005) Vaccine , vol.23 , Issue.22 , pp. 2876-2880
    • Kurugol, Z.1    Mutlubas, F.2    Ozacar, T.3
  • 21
    • 20444367613 scopus 로고    scopus 로고
    • Immunogenicity of two paediatric doses of monovalent hepatitis B or combined hepatitis A and B vaccine in 8-10-year-old children
    • DOI 10.1016/j.vaccine.2004.07.022, PII S0264410X04005444
    • Duval B, Gilca V, Boulianne N, Deceuninck G, Rochette L, De Serres G. Immunogenicity of two paediatric doses ofmonovalent hepatitis B or combined hepatitis A and B vaccine in 8-10-year-old children. Vaccine 23(31), 4082-4087 (2005). (Pubitemid 40800670)
    • (2005) Vaccine , vol.23 , Issue.31 , pp. 4082-4087
    • Duval, B.1    Gilca, V.2    Boulianne, N.3    Deceuninck, G.4    Rochette, L.5    De Serres, G.6
  • 22
    • 40649093771 scopus 로고    scopus 로고
    • Long-term antibody persistence induced by a combined hepatitis A and B vaccine in children and adolescents
    • Diaz-Mitoma F, Law B, Subramanya A, Hoet B. Long-term antibody persistence induced by a combined hepatitis A and B vaccine in children and adolescents. Vaccine 26(14), 1759-1763 (2008).
    • (2008) Vaccine , vol.26 , Issue.14 , pp. 1759-1763
    • Diaz-Mitoma, F.1    Law, B.2    Subramanya, A.3    Hoet, B.4
  • 23
    • 30944452364 scopus 로고    scopus 로고
    • Combined typhoid fever and hepatitis A vaccine: Comparison of immunogenicity and safety to concomitant monovalent vaccine over 3 years
    • Overbosch D, Peyron F, Picot N et al. Combined typhoid fever and hepatitis A vaccine: comparison of immunogenicity and safety to concomitant monovalent vaccine over 3 years. J. Travel Med. 12(6), 319-326 (2005). (Pubitemid 43111736)
    • (2005) Journal of Travel Medicine , vol.12 , Issue.6 , pp. 319-326
    • Overbosch, D.1    Peyron, F.2    Picot, N.3    Varichon, J.-P.4    Dumas, R.5    Chambonneau, L.6    Weber, F.7
  • 24
    • 7444264760 scopus 로고    scopus 로고
    • Comparison of two combined vaccines against typhoid fever and hepatitis A in healthy adults
    • DOI 10.1016/j.vaccine.2004.05.040, PII S0264410X04006450
    • Beeching NJ, Clarke PD, Kitchin NR, Pirmohamed J, Veitch K, Weber F. Comparison of two combined vaccines against typhoid fever and hepatitis A in healthy adults. Vaccine 23(1), 29-35 (2004). (Pubitemid 39446356)
    • (2004) Vaccine , vol.23 , Issue.1 , pp. 29-35
    • Beeching, N.J.1    Clarke, P.D.2    E. Kitchin, N.R.3    Pirmohamed, J.4    Veitch, K.5    Weber, F.6
  • 25
    • 0142258054 scopus 로고    scopus 로고
    • A combined dual-chamber typhoid/hepatitis A vaccine as a booster dose in hepatitis A primed adults
    • DOI 10.1016/j.vaccine.2003.08.013
    • Beran J, Chlibek R, Weber F. A combined dual-chamber typhoid/hepatitis A vaccine as a booster dose in hepatitis A primed adults. Vaccine 21(32), 4650-4654 (2003). (Pubitemid 37329858)
    • (2003) Vaccine , vol.21 , Issue.32 , pp. 4650-4654
    • Beran, J.1    Chlibek, R.2    Weber, F.3
  • 26
    • 44349123571 scopus 로고    scopus 로고
    • Advisory committee on immunization practices centers for disease control and prevention CDC human rabies prevention - United States 2008: Recommendations of the advisory committee on immunization practices
    • RR-3
    • Manning SE, Rupprecht CE, Fishbein D et al.; Advisory Committee on Immunization Practices Centers for Disease Control and Prevention (CDC). Human rabies prevention - United States, 2008: recommendations of the Advisory Committee on Immunization Practices. MMWR Recomm. Rep. 57(RR-3), 1-28 (2008).
    • (2008) MMWR Recomm. Rep. , vol.57 , pp. 1-28
    • Manning, S.E.1    Rupprecht, C.E.2    Fishbein, D.3
  • 27
    • 77949896373 scopus 로고    scopus 로고
    • Centers for disease control and prevention CDC use of a reduced 4-dose vaccine schedule for postexposure prophylaxis to prevent human rabies: Recommendations of the advisory committee on immunization practices
    • RR-2
    • Rupprecht CE, Briggs D, Brown CM et al.; Centers for Disease Control and Prevention (CDC). Use of a reduced (4-dose) vaccine schedule for postexposure prophylaxis to prevent human rabies: recommendations of the Advisory Committee on Immunization Practices. MMWR Recomm. Rep. 59(RR-2), 1-9 (2010).
    • (2010) MMWR Recomm. Rep. , vol.59 , pp. 1-9
    • Rupprecht, C.E.1    Briggs, D.2    Brown, C.M.3
  • 28
    • 78751590009 scopus 로고    scopus 로고
    • Rabies vaccines: WHO position paper
    • WHO
    • WHO. Rabies vaccines: WHO position paper. Wkly Epidemiol. Rec. 85(32), 309-320 (2010).
    • (2010) Wkly Epidemiol. Rec. , vol.85 , Issue.32 , pp. 309-320
  • 29
    • 77956401638 scopus 로고    scopus 로고
    • Seroconversion following incomplete human rabies postexposure prophylaxis
    • Robertson K, Recuenco S, Niezgoda M, Garcia EJ, Rupprecht CE. Seroconversion following incomplete human rabies postexposure prophylaxis. Vaccine 28(39), 6523-6526 (2010).
    • (2010) Vaccine , vol.28 , Issue.39 , pp. 6523-6526
    • Robertson, K.1    Recuenco, S.2    Niezgoda, M.3    Garcia, E.J.4    Rupprecht, C.E.5
  • 30
    • 72049088299 scopus 로고    scopus 로고
    • Failure of rabies postexposure prophylaxis in patients presenting with unusual manifestations
    • Shantavasinkul P, Tantawichien T, Wacharapluesadee S et al. Failure of rabies postexposure prophylaxis in patients presenting with unusual manifestations. Clin. Infect. Dis. 50(1), 77-79 (2010).
    • (2010) Clin. Infect. Dis. , vol.50 , Issue.1 , pp. 77-79
    • Shantavasinkul, P.1    Tantawichien, T.2    Wacharapluesadee, S.3
  • 31
    • 33947132657 scopus 로고    scopus 로고
    • Animal-associated injuries and related diseases among returned travellers: A review of the GeoSentinel Surveillance Network
    • DOI 10.1016/j.vaccine.2006.12.034, PII S0264410X06013338
    • Gautret P, Schwartz E, Shaw M et al.; GeoSentinel Surveillance Network. Animal-associated injuries and related diseases among returned travellers: a review of the GeoSentinel Surveillance Network. Vaccine 25(14), 2656-2663 (2007). (Pubitemid 46400926)
    • (2007) Vaccine , vol.25 , Issue.14 , pp. 2656-2663
    • Gautret, P.1    Schwartz, E.2    Shaw, M.3    Soula, G.4    Gazin, P.5    Delmont, J.6    Parola, P.7    Soavi, M.J.8    Matchett, E.9    Brown, G.10    Torresi, J.11
  • 33
    • 77955701149 scopus 로고    scopus 로고
    • Prevention and control of influenza with vaccines recommendations of the advisory committee on immunization practices ACIP 2010
    • CDC RR-8
    • CDC. Prevention and control of influenza with vaccines. Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm. Rep. 59(RR-8), 1-68 (2010).
    • (2010) MMWR Recomm. Rep. , Issue.59 , pp. 1-68
  • 34
    • 77949702062 scopus 로고    scopus 로고
    • Japanese encephalitis vaccines: Recommendations of the advisory committee on immunization practices ACIP
    • CDC RR-1
    • CDC. Japanese encephalitis vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm. Rep. 59(RR-1), 1-27 (2010).
    • (2010) MMWR Recomm. Rep. , vol.59 , pp. 1-27
  • 35
    • 77952687751 scopus 로고    scopus 로고
    • Japanese encephalitis in travelers from non-endemic countries 1973-2008
    • Hills SI, Griggs AC, Fischer M. Japanese encephalitis in travelers from non-endemic countries, 1973-2008. Am. J. Trop. Med. Hyg. 82, 930-936 (2010).
    • (2010) Am. J. Trop. Med. Hyg. , vol.82 , pp. 930-936
    • Hills, S.I.1    Griggs, A.C.2    Fischer, M.3
  • 36
    • 79952672355 scopus 로고    scopus 로고
    • Japanese encephalitis in two children - United States 2010
    • CDC.
    • CDC. Japanese encephalitis in two children - United States, 2010. MMWR Morb. Mortal. Wkly Rep. 60(9), 276-278 (2011).
    • (2011) MMWR Morb. Mortal. Wkly Rep. , vol.60 , Issue.9 , pp. 276-278
  • 37
    • 67650581310 scopus 로고    scopus 로고
    • Japanese encephalitis among three US travelers returning from Asia 2003-2008
    • CDC.
    • CDC. Japanese encephalitis among three US travelers returning from Asia, 2003-2008. MMWR Morb. Mortal. Wkly Rep. 58(27), 737-740 (2009).
    • (2009) MMWR Morb. Mortal. Wkly Rep. , vol.58 , Issue.27 , pp. 737-740
  • 38
    • 61549095001 scopus 로고    scopus 로고
    • Comparison of a single high-dose vaccination regimen to the standard regimen for the investigational Japanese encephalitis vaccine IC51: A randomized observer-blind controlled phase 3 study
    • Schuller E, Klade CS, Wölfl G, Kaltenböck A, Dewasthaly S, Tauber E. Comparison of a single, high-dose vaccination regimen to the standard regimen for the investigational Japanese encephalitis vaccine, IC51: a randomized, observer-blind, controlled Phase 3 study. Vaccine 27(15), 2188-2193 (2009).
    • (2009) Vaccine , vol.27 , Issue.15 , pp. 2188-2193
    • Schuller, E.1    Klade, C.S.2    Wölfl, G.3    Kaltenböck, A.4    Dewasthaly, S.5    Tauber, E.6
  • 39
    • 47849106825 scopus 로고    scopus 로고
    • Long-term immunogenicity of the new vero cell-derived inactivated japanese encephalitis virus vaccine IC51: Six and 12 month results of a multicenter follow-up phase 3 study
    • Schuller E, Jilma B, Voicu V et al. Long-term immunogenicity of the new Vero cell-derived, inactivated Japanese encephalitis virus vaccine IC51: six and 12 month results of a multicenter follow-up Phase 3 study. Vaccine 26, 4382-4386 (2008).
    • (2008) Vaccine , vol.26 , pp. 4382-4386
    • Schuller, E.1    Jilma, B.2    Voicu, V.3
  • 40
    • 77954959942 scopus 로고    scopus 로고
    • Long-term immunity and immune response to a booster dose following vaccination with the inactivated Japanese encephalitis vaccine Ixiaro IC51
    • Dubischar-Kastner K, Eder S, Buerger V et al. Long-term immunity and immune response to a booster dose following vaccination with the inactivated Japanese encephalitis vaccine Ixiaro, IC51. Vaccine 28, 5197-5202 (2010).
    • (2010) Vaccine , vol.28 , pp. 5197-5202
    • Dubischar-Kastner, K.1    Eder, S.2    Buerger, V.3
  • 41
    • 84954358400 scopus 로고    scopus 로고
    • Effect of pre-existing anti-tick-borne encephalitis virus immunity on neutralising antibody response to the vero cell-derived inactivated Japanese encephalitis virus vaccine candidate IC51
    • Schuller E, Klade CS, Heinz FX et al. Effect of pre-existing anti-tick-borne encephalitis virus immunity on neutralising antibody response to the Vero cell-derived, inactivated Japanese encephalitis virus vaccine candidate IC51. Vaccine 26(48), 6151-6156 (2008).
    • (2008) Vaccine , vol.26 , Issue.48 , pp. 6151-6156
    • Schuller, E.1    Klade, C.S.2    Heinz, F.X.3
  • 42
    • 79952248906 scopus 로고    scopus 로고
    • Long term immunity following a booster dose of the inactivated Japanese encephalitis vaccine Ixiaro IC51
    • Eder S, Dubischar-Kastner K, Firbas C et al. Long term immunity following a booster dose of the inactivated Japanese encephalitis vaccine Ixiaro, IC51. Vaccine 29, 2607-2612 (2011).
    • (2011) Vaccine , vol.29 , pp. 2607-2612
    • Eder, S.1    Dubischar-Kastner, K.2    Firbas, C.3
  • 43
    • 79958287508 scopus 로고    scopus 로고
    • Recommendations for use of a booster dose of inactivated vero cell culture-derived Japanese encephalitis vaccine - Advisory committee on immunization practices 2011
    • CDC.
    • CDC. Recommendations for use of a booster dose of inactivated vero cell culture-derived Japanese encephalitis vaccine - Advisory Committee on Immunization Practices, 2011. MMWR Morb. Mortal. Wkly Rep. 60(20), 661-663 (2011).
    • (2011) MMWR Morb. Mortal. Wkly Rep. , vol.60 , Issue.20 , pp. 661-663
  • 45
    • 71349087878 scopus 로고    scopus 로고
    • Immunogenicity and safety of IXIARO IC51 in a phase II study in healthy Indian children between 1 and 3 years of age
    • Kaltenbock A, Dubischar-Kastner K, Schuller E et al. Immunogenicity and safety of IXIARO (IC51) in a Phase II study in healthy Indian children between 1 and 3 years of age. Vaccine 28, 834-839 (2010).
    • (2010) Vaccine , vol.28 , pp. 834-839
    • Kaltenbock, A.1    Dubischar-Kastner, K.2    Schuller, E.3
  • 46
  • 47
    • 79958249448 scopus 로고    scopus 로고
    • Update on Japanese encephalitis vaccine for children -United States may 2011
    • CDC
    • CDC. Update on Japanese encephalitis vaccine for children -United States, may 2011. MMWR Morb. Mortal. Wkly Rep. 60(20), 664-665 (2011).
    • (2011) MMWR Morb. Mortal. Wkly Rep. , vol.60 , Issue.20 , pp. 664-665
  • 48
    • 79954802756 scopus 로고    scopus 로고
    • The Global Meningococcal Initiative: Recommendations for reducing the global burden of meningococcal disease
    • Harrison LH, Pelton SI, Wilder-Smith A et al. The Global Meningococcal Initiative: recommendations for reducing the global burden of meningococcal disease. Vaccine 29(18), 3363-3371 (2011).
    • (2011) Vaccine , vol.29 , Issue.18 , pp. 3363-3371
    • Harrison, L.H.1    Pelton, S.I.2    Wilder-Smith, A.3
  • 49
    • 34548436899 scopus 로고    scopus 로고
    • Meningococcal vaccine in travelers
    • DOI 10.1097/QCO.0b013e3282a64700, PII 0000143220071000000003
    • Wilder-Smith A. Meningococcal vaccine in travelers. Curr. Opin. Infect. Dis. 20(5), 454-460 (2007). (Pubitemid 47359640)
    • (2007) Current Opinion in Infectious Diseases , vol.20 , Issue.5 , pp. 454-460
    • Wilder-Smith, A.1
  • 51
    • 0023724202 scopus 로고
    • Group A meningococcal carriage in travelers returning from Saudi Arabia
    • Moore PS, Harrison LH, Telzak EE, Ajello GW, Broome CV. Group A meningococcal carriage in travelers returning from Saudi Arabia. JAMA 260(18), 1686-2689 (1988).
    • (1988) JAMA , vol.260 , Issue.18 , pp. 1686-2689
    • Moore, P.S.1    Harrison, L.H.2    Telzak, E.E.3    Ajello, G.W.4    Broome, C.V.5
  • 52
    • 0036133689 scopus 로고    scopus 로고
    • Meningococcal disease and travel
    • DOI 10.1086/323403
    • Memish ZA. Meningococcal disease and travel. Clin. Infect. Dis. 34, 84-90 (2002). (Pubitemid 33152671)
    • (2002) Clinical Infectious Diseases , vol.34 , Issue.1 , pp. 84-90
    • Memish, Z.A.1
  • 54
    • 70349560669 scopus 로고    scopus 로고
    • Updated recommendation from the advisory committee on immunization practices ACIP for revaccination of persons at prolonged increased risk for meningococcal disease
    • CDC
    • CDC. Updated recommendation from the Advisory Committee on Immunization Practices (ACIP) for revaccination of persons at prolonged increased risk for meningococcal disease. MMWR Morb. Mortal. Wkly Rep. 58(37), 1042-1043 (2009).
    • (2009) MMWR Morb. Mortal. Wkly Rep. , vol.58 , Issue.37 , pp. 1042-1043
  • 55
    • 63449126648 scopus 로고    scopus 로고
    • Immunogenicity and immune memory of a nonadjuvanted quadrivalent meningococcal glycoconjugate vaccine in infants
    • Perrett KP, Snape MD, Ford KJ et al. Immunogenicity and immune memory of a nonadjuvanted quadrivalent meningococcal glycoconjugate vaccine in infants. Pediatr. Infect. Dis. J. 28(3), 186-193 (2009).
    • (2009) Pediatr. Infect. Dis. J. , vol.28 , Issue.3 , pp. 186-193
    • Perrett, K.P.1    Snape, M.D.2    Ford, K.J.3
  • 56
    • 77949311018 scopus 로고    scopus 로고
    • Licensure of a meningococcal conjugate vaccine menveo and guidance for use - Advisory committee on immunization practices ACIP 2010
    • CDC.
    • CDC. Licensure of a meningococcal conjugate vaccine (Menveo) and guidance for use - Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Morb. Mortal. Wkly Rep. 59(9), 273 (2010).
    • (2010) MMWR Morb. Mortal. Wkly Rep. , vol.59 , Issue.9 , pp. 273
  • 57
    • 78650498911 scopus 로고    scopus 로고
    • Menveo®: A novel quadrivalent meningococcal CRM197 conjugate vaccine against serogroups A C W-135 and Y
    • Cooper B, DeTora L, Stoddard J. Menveo®: a novel quadrivalent meningococcal CRM197 conjugate vaccine against serogroups A, C, W-135 and Y. Expert Rev. Vaccines 10(1), 21-33 (2011).
    • (2011) Expert Rev. Vaccines , vol.10 , Issue.1 , pp. 21-33
    • Cooper, B.1    DeTora, L.2    Stoddard, J.3
  • 58
    • 79251607440 scopus 로고    scopus 로고
    • Updated recommendations for use of meningococcal conjugate vaccines - Advisory committee on immunization practices ACIP 2010
    • CDC.
    • CDC. Updated recommendations for use of meningococcal conjugate vaccines - Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Morb. Mortal. Wkly Rep. 60(3), 72-76 (2011).
    • (2011) MMWR Morb. Mortal. Wkly Rep. , vol.60 , Issue.3 , pp. 72-76
  • 59
    • 0035436653 scopus 로고    scopus 로고
    • Yellow fever: An update
    • DOI 10.1016/S1473-3099(01)00016-0, PII S1473309901000160
    • Monath TP. Yellow fever: an update. Lancet Infect. Dis. 1(1), 11-20 (2001). (Pubitemid 33586036)
    • (2001) Lancet Infectious Diseases , vol.1 , Issue.1 , pp. 11-20
    • Monath, T.P.1
  • 60
    • 79952206301 scopus 로고    scopus 로고
    • WHO yellow fever in Africa and central and south America 2008-2009
    • WHO. Yellow fever in Africa and Central and South America, 2008-2009. Wkly Epidemiol. Rec. 86(4), 25-36 (2011).
    • (2011) Wkly Epidemiol. Rec. , vol.86 , Issue.4 , pp. 25-36
  • 61
    • 85054106262 scopus 로고    scopus 로고
    • For the informal world health organization working group on geographic risk for yellow fever the revised global yellow fever risk map and recommendations for vaccination 2010: An international collaborative effort
    • In Press
    • Jentes ES, Poumerol G, Gershman MD et al. for the Informal World Health Organization Working Group on Geographic Risk for Yellow Fever. The revised global yellow fever risk map and recommendations for vaccination 2010: an international collaborative effort. Lancet Infect. Dis. (2011) (In Press).
    • (2011) Lancet Infect. Dis.
    • Jentes, E.S.1    Poumerol, G.2    Gershman, M.D.3
  • 62
    • 0003987631 scopus 로고    scopus 로고
    • WHO 2nd Edition WHO Press.Geneva Switzerland
    • WHO. International Health Regulations (2nd Edition). WHO Press, Geneva, Switzerland (2005).
    • (2005) International Health Regulations
  • 63
    • 0003864029 scopus 로고    scopus 로고
    • WHO WHO Press Geneva Switzerland
    • WHO. International Travel and Health. WHO Press, Geneva, Switzerland (2011).
    • (2011) International Travel Health
  • 64
    • 40949091022 scopus 로고    scopus 로고
    • WHO outbreak news yellow fever Paraguay
    • WHO. Outbreak news. Yellow fever, Paraguay. Wkly Epidemiol. Rec. 83(12), 105 (2008).
    • (2008) Wkly Epidemiol. Rec. , vol.83 , Issue.12 , pp. 105
  • 65
    • 85159011903 scopus 로고    scopus 로고
    • Yellow fever vaccine
    • 5th Edition Plotkin SA Orenstien WA Offit PA Eds Saunders PA USA
    • Monath TP, Cetron MS, Teuwen DE. Yellow fever vaccine. In: Vaccines (5th Edition). Plotkin SA, Orenstien WA, Offit PA (Eds). Saunders, PA, USA, 959-1055 (2008).
    • (2008) Vaccines , pp. 959-1055
    • Monath, T.P.1    Cetron, M.S.2    Teuwen, D.E.3
  • 66
    • 77955100138 scopus 로고    scopus 로고
    • Yellow fever vaccine: Recommendations of the advisory committee on immunization practices ACIP
    • RR-7
    • Staples JE, Gershman M, Fischer M. Yellow fever vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm. Rep. 59(RR-7), 1-27 (2010).
    • (2010) MMWR Recomm. Rep. , vol.59 , pp. 1-27
    • Staples, J.E.1    Gershman, M.2    Fischer, M.3
  • 67
    • 55249101442 scopus 로고    scopus 로고
    • Adverse event reports following yellow fever vaccination
    • Lindsey NP, Schroeder BA, Miller ER et al. Adverse event reports following yellow fever vaccination. Vaccine 26(48), 6077-6082 (2008).
    • (2008) Vaccine , vol.26 , Issue.48 , pp. 6077-6082
    • Lindsey, N.P.1    Schroeder, B.A.2    Miller, E.R.3
  • 68
    • 73949096411 scopus 로고    scopus 로고
    • Short report: Incidence of yellow fever vaccineassociated neurotropic disease
    • Guimard T, Minjolle S, Polard E et al. Short report: Incidence of yellow fever vaccineassociated neurotropic disease. Am. J. Trop. Med. Hyg. 81(6), 1141-1143 (2009).
    • (2009) Am. J. Trop. Med. Hyg. , vol.81 , Issue.6 , pp. 1141-1143
    • Guimard, T.1    Minjolle, S.2    Polard, E.3
  • 70
    • 70349435917 scopus 로고    scopus 로고
    • Viscerotropic disease following yellow fever vaccination in Peru
    • Whittembury A, Ramirez G, Hernandez H et al. Viscerotropic disease following yellow fever vaccination in Peru. Vaccine 27(43), 5974-5981 (2009).
    • (2009) Vaccine , vol.27 , Issue.43 , pp. 5974-5981
    • Whittembury, A.1    Ramirez, G.2    Hernandez, H.3
  • 71
    • 74549202279 scopus 로고    scopus 로고
    • Clinical and immunological insights on severe adverse neurotropic and viscerotropic disease following 17D yellow fever vaccination
    • Silva ML, Espirito-Santo LR, Martins MA et al. Clinical and immunological insights on severe, adverse neurotropic and viscerotropic disease following 17D yellow fever vaccination. Clin. Vaccine Immunol. 17(1), 118-126 (2010).
    • (2010) Clin. Vaccine Immunol. , vol.17 , Issue.1 , pp. 118-126
    • Silva, M.L.1    Espirito-Santo, L.R.2    Martins, M.A.3
  • 73
    • 48749110535 scopus 로고    scopus 로고
    • Case of yellow fever vaccine-associated viscerotropic disease with prolonged viremia, robust adaptive immune responses and polymorphisms in CCR5 and RANTES genes
    • Pulendran B, Miller J, Querec TD et al. Case of yellow fever vaccine-associated viscerotropic disease with prolonged viremia, robust adaptive immune responses, and polymorphisms in CCR5 and RANTES genes. J. Infect. Dis. 198(4), 500-507 (2008).
    • (2008) J. Infect. Dis. , vol.198 , Issue.4 , pp. 500-507
    • Pulendran, B.1    Miller, J.2    Querec, T.D.3
  • 74
    • 59649129816 scopus 로고    scopus 로고
    • Yellow fever vaccine induces integrated multilineage and polyfunctional immune responses
    • Gaucher D, Therrien R, Kettaf N et al. Yellow fever vaccine induces integrated multilineage and polyfunctional immune responses. J. Exp. Med. 205(13), 3119-3131 (2008).
    • (2008) J. Exp. Med. , vol.205 , Issue.13 , pp. 3119-3131
    • Gaucher, D.1    Therrien, R.2    Kettaf, N.3
  • 76
    • 4444359788 scopus 로고    scopus 로고
    • For the yellow fever vaccine safety working group history of thymoma and yellow fever vaccination letter
    • Barwick Eidex R, for the Yellow Fever Vaccine Safety Working Group. History of thymoma and yellow fever vaccination (letter). Lancet 364(9438), 936 (2004).
    • (2004) Lancet , vol.364 , Issue.9438 , pp. 936
    • Barwick Eidex, R.1
  • 77
    • 79952319151 scopus 로고    scopus 로고
    • Case report: Probable transmission of vaccine strain of yellow fever virus to an infant via breast milk
    • Kuhn S, Twele-Montecinos L, Macdonald J, Webster P, Law B. Case report: probable transmission of vaccine strain of yellow fever virus to an infant via breast milk. CMAJ 183(4), E243-E245 (2011).
    • (2011) CMAJ , vol.183 , Issue.4
    • Kuhn, S.1    Twele-Montecinos, L.2    Macdonald, J.3    Webster, P.4    Law, B.5
  • 78
    • 77649220044 scopus 로고    scopus 로고
    • WHO global advisory committee on vaccine safety
    • 3-4 December 2009.
    • WHO. Global Advisory Committee on Vaccine Safety, 3-4 December 2009. Wkly Epidemiol. Rec. 85(5), 29-33 (2010).
    • (2010) Wkly Epidemiol. Rec. , vol.85 , Issue.5 , pp. 29-33
  • 79
    • 76749123835 scopus 로고    scopus 로고
    • Transmission of yellow fever vaccine virus through breast-feeding - Brazil 2009
    • CDC.
    • CDC. Transmission of yellow fever vaccine virus through breast-feeding - Brazil, 2009. MMWR Morb. Mortal. Wkly Rep. 59(5), 130-132 (2010).
    • (2010) MMWR Morb. Mortal. Wkly Rep. , vol.59 , Issue.5 , pp. 130-132
  • 81
    • 0345337263 scopus 로고    scopus 로고
    • Exposure to yellow fever vaccine in early pregnancy
    • DOI 10.1016/S0264-410X(98)00051-6, PII S0264410X98000516
    • Robert E, Vial T, Schaefer C, Arnon J, Reuvers M. Exposure to yellow fever vaccine in early pregnancy. Vaccine 17, 283-285 (1999). (Pubitemid 28552788)
    • (1999) Vaccine , vol.17 , Issue.3 , pp. 283-285
    • Robert, E.1    Vial, T.2    Schaefer, C.3    Arnon, J.4    Reuvers, M.5
  • 82
    • 0027362762 scopus 로고
    • Congenital yellow fever virus infection after immunization in pregnancy
    • Tsai TF, Paul R, Lynberg MC, Letson GW. Congenital yellow fever virus infection after immunization in pregnancy. J. Infect. Dis. 168, 1520-1523 (1993). (Pubitemid 23344916)
    • (1993) Journal of Infectious Diseases , vol.168 , Issue.6 , pp. 1520-1523
    • Tsai, T.F.1    Paul, R.2    Lynberg, M.C.3    Letson, G.W.4
  • 83
    • 0027234707 scopus 로고
    • Yellow fever vaccination and pregnancy: A four-year prospective study
    • Nasidi A, Monath TP, Vandenberg J et al. Yellow fever vaccination and pregnancy: a four-year prospective study. Trans. R. Soc. Trop. Med. Hyg. 87, 337-339 (1993).
    • (1993) Trans. R. Soc. Trop. Med. Hyg. , vol.87 , pp. 337-339
    • Nasidi, A.1    Monath, T.P.2    Vandenberg, J.3
  • 84
    • 60549101423 scopus 로고    scopus 로고
    • Immunogenicity and safety of yellow fever vaccination for 102 HIV-infected patients
    • Veit O, Niedrig M, Chapuis-Taillard C et al. Immunogenicity and safety of yellow fever vaccination for 102 HIV-infected patients. Clin. Infect. Dis. 48(5), 659-666 (2009).
    • (2009) Clin. Infect. Dis. , vol.48 , Issue.5 , pp. 659-666
    • Veit, O.1    Niedrig, M.2    Chapuis-Taillard, C.3
  • 85
    • 79958836540 scopus 로고    scopus 로고
    • WHO vaccines against tick-borne encephalitis: WHO position paper
    • WHO. Vaccines against tick-borne encephalitis: WHO position paper. Wkly Epidemiol. Rec. 86(24), 241-256 (2011).
    • (2011) Wkly Epidemiol. Rec. , vol.86 , Issue.24 , pp. 241-256
  • 86
    • 77949982454 scopus 로고    scopus 로고
    • CDC tick-borne encephalitis among US travelers to europe and Asia - 2000-2009
    • CDC. Tick-borne encephalitis among U.S. travelers to Europe and Asia - 2000-2009. MMWR Morb. Mortal. Wkly Rep. 59(11), 335-338 (2010).
    • (2010) MMWR Morb. Mortal. Wkly Rep. , vol.59 , Issue.11 , pp. 335-338
  • 87
    • 33846204617 scopus 로고    scopus 로고
    • Tick-borne encephalitis TBE vaccination: Applying the most suitable vaccination schedule
    • Schöndorf I, Beran J, Cizkova D, Lesna V, Banzhoff A, Zent O. Tick-borne encephalitis (TBE) vaccination: applying the most suitable vaccination schedule. Vaccine 25, 1470-1476 (2007).
    • (2007) Vaccine , vol.25 , pp. 1470-1476
    • Schöndorf, I.1    Beran, J.2    Cizkova, D.3    Lesna, V.4    Banzhoff, A.5    Zent, O.6
  • 88
    • 33947704636 scopus 로고    scopus 로고
    • Tick-borne encephalitis (TBE) vaccination in children: Advantage of the rapid immunization schedule (i.e., days O, 7, 21)
    • Schoendorf I, Ternak G, Oroszlàn G, Nicolay U, Banzhoff A, Zent O. Tick-borne encephalitis (TBE) vaccination in children: advantage of the rapid immunization schedule (i.e., days 0, 7, 21). Hum. Vaccines 2, 42-47 (2007). (Pubitemid 46493604)
    • (2007) Human Vaccines , vol.3 , Issue.2 , pp. 42-47
    • Schoendorf, I.1    Ternak, G.2    Oroszlan, G.3    Nicolay, U.4    Banzhoff, A.5    Zent, O.6
  • 90
    • 79961085080 scopus 로고    scopus 로고
    • WHO Cholera 2010
    • WHO. Cholera, 2010. Wkly Epidemiol. Rec. 86(31), 325-339 (2011).
    • (2011) Wkly Epidemiol. Rec. , vol.86 , Issue.31 , pp. 325-339
  • 91
    • 78649874927 scopus 로고    scopus 로고
    • A national cholera vaccine stockpile - A new humanitarian and diplomatic resource
    • Waldor MK, Hotez PJ, Clemens JD. A national cholera vaccine stockpile - a new humanitarian and diplomatic resource. N. Engl. J. Med. 363(24), 2279-2282 (2010).
    • (2010) N. Engl. J. Med. , vol.363 , Issue.24 , pp. 2279-2282
    • Waldor, M.K.1    Hotez, P.J.2    Clemens, J.D.3
  • 93
    • 33646682630 scopus 로고    scopus 로고
    • Oral cholera vaccines: Use in clinical practice
    • DOI 10.1016/S1473-3099(06)70494-7, PII S1473309906704947
    • Hill DR, Ford L, Lalloo DG. Oral cholera vaccines: use in clinical practice. Lancet Infect. Dis. 6, 361-373 (2006). (Pubitemid 43737274)
    • (2006) Lancet Infectious Diseases , vol.6 , Issue.6 , pp. 361-373
    • Hill, D.R.1    Ford, L.2    Lalloo, D.G.3
  • 94
    • 58449133479 scopus 로고    scopus 로고
    • Cost-benefit of WC/rBS oral cholera vaccine for vaccination against ETEC-caused travelers diarrhea
    • Lundkvist J, Steffen R, Jönsson B. Cost-benefit of WC/rBS oral cholera vaccine for vaccination against ETEC-caused travelers' diarrhea. J. Travel Med. 16(1), 28-34 (2009).
    • (2009) J. Travel Med. , vol.16 , Issue.1 , pp. 28-34
    • Lundkvist, J.1    Steffen, R.2    Jönsson, B.3
  • 95
    • 55049084757 scopus 로고    scopus 로고
    • Geographic expansion of dengue: The impact of international travel
    • x
    • Wilder-Smith A, Gubler DJ. Geographic expansion of dengue: the impact of international travel. Med. Clin. North. Am. 92(6), 1377-1390, x (2008).
    • (2008) Med. Clin. North. Am. , vol.92 , Issue.6 , pp. 1377-1390
    • Wilder-Smith, A.1    Gubler, D.J.2
  • 96
    • 80053984779 scopus 로고    scopus 로고
    • Update on dengue: Epidemiology virus evolution antiviral drugs and vaccine development
    • Wilder-Smith A, Ooi EE, Vasudevan SG, Gubler DJ. Update on dengue: epidemiology, virus evolution, antiviral drugs, and vaccine development. Curr. Infect. Dis. Rep. 12(3), 157-164 (2010).
    • (2010) Curr. Infect. Dis. Rep. , vol.12 , Issue.3 , pp. 157-164
    • Wilder-Smith, A.1    Ooi, E.E.2    Vasudevan, S.G.3    Gubler, D.J.4
  • 100
    • 45849101684 scopus 로고    scopus 로고
    • Dengue vaccines for travelers
    • DOI 10.1586/14760584.7.5.569
    • Wilder-Smith A, Deen JL. Dengue vaccines for travelers. Expert Rev. Vaccines 7(5), 569-578 (2008). (Pubitemid 351881341)
    • (2008) Expert Review of Vaccines , vol.7 , Issue.5 , pp. 569-578
    • Wilder-Smith, A.1    Deen, J.L.2
  • 101
    • 36549054066 scopus 로고    scopus 로고
    • Dengue and yellow fever - Challenges for the development and use of vaccines
    • DOI 10.1056/NEJMp0707161
    • Monath TP. Dengue and yellow fever - challenges for the development and use of vaccines. N. Engl. J. Med. 357(22), 2222-2225 (2007). (Pubitemid 350190752)
    • (2007) New England Journal of Medicine , vol.357 , Issue.22 , pp. 2222-2225
    • Monath, T.P.1
  • 102
    • 70349576213 scopus 로고    scopus 로고
    • Recent progress on sanofi pasteurs dengue vaccine candidate
    • Lang J. Recent progress on sanofi pasteur's dengue vaccine candidate. J. Clin. Virol. 46(Suppl. 2), S20-S24 (2009).
    • (2009) J. Clin. Virol. , vol.46 , Issue.2
    • Lang, J.1
  • 103
    • 40549089216 scopus 로고    scopus 로고
    • Recombinant chimeric virus with wild-type dengue 4 virus premembrane and envelope and virulent yellow fever virus Asibi backbone sequences is dramatically attenuated in nonhuman primates
    • DOI 10.1086/527329
    • McGee CE, Lewis MG, Claire MS et al. Recombinant chimeric virus with wild-type dengue 4 virus premembrane and envelope and virulent yellow fever virus Asibi backbone sequences is dramatically attenuated in nonhuman primates. J. Infect. Dis. 197(5), 693-697 (2008). (Pubitemid 351364469)
    • (2008) Journal of Infectious Diseases , vol.197 , Issue.5 , pp. 693-697
    • McGee, C.E.1    Lewis, M.G.2    St. Claire, M.3    Wagner, W.4    Lang, J.5    Guy, B.6    Tsetsarkin, K.7    Higgs, S.8    Decelle, T.9
  • 106
    • 77956911340 scopus 로고    scopus 로고
    • Meningococcal disease in travelers: A rare but devastating disease
    • Wilder-Smith A. Meningococcal disease in travelers: a rare but devastating disease. J. Travel Med. 17(Suppl.), 1-2 (2010).
    • (2010) J. Travel Med. , vol.17 , pp. 1-2
    • Wilder-Smith, A.1
  • 107
    • 77951646506 scopus 로고    scopus 로고
    • Review of meningococcal group B vaccines
    • Granoff DM. Review of meningococcal group B vaccines. Clin. Infect. Dis. 50(Suppl. 2), S54-S65 (2010).
    • (2010) Clin. Infect. Dis. , vol.50 , Issue.2
    • Granoff, D.M.1
  • 108
    • 79958035895 scopus 로고    scopus 로고
    • Recombinant protein meningococcal serogroup B vaccine combined with outer membrane vesicles
    • Bai X, Findlow J, Borrow R. Recombinant protein meningococcal serogroup B vaccine combined with outer membrane vesicles. Expert Opin. Biol. Ther. 11(7), 969-985 (2011).
    • (2011) Expert Opin. Biol. Ther. , vol.11 , Issue.7 , pp. 969-985
    • Bai, X.1    Findlow, J.2    Borrow, R.3
  • 110
    • 45949093410 scopus 로고    scopus 로고
    • Malaria vaccines: A toy for travelers or a tool for eradication?
    • DOI 10.1586/14760584.7.5.597
    • Genton B. Malaria vaccines: a toy for travelers or a tool for eradication? Expert Rev. Vaccines 7(5), 597-611 (2008). (Pubitemid 351890331)
    • (2008) Expert Review of Vaccines , vol.7 , Issue.5 , pp. 597-611
    • Genton, B.1
  • 111
    • 67650697101 scopus 로고    scopus 로고
    • Long-term safety and efficacy of the RTS,S/AS02A malaria vaccine in mozambican children
    • Sacarlal J, Aide P, Aponte JJ et al. Long-term safety and efficacy of the RTS,S/AS02A malaria vaccine in Mozambican children. J. Infect. Dis. 200(3), 329-336 (2009).
    • (2009) J. Infect. Dis. , vol.200 , Issue.3 , pp. 329-336
    • Sacarlal, J.1    Aide, P.2    Aponte, J.J.3
  • 112
    • 57649115306 scopus 로고    scopus 로고
    • Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of age
    • Bejon P, Lusingu J, Olotu A et al. Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of age. N. Engl. J. Med. 359(24), 2521-2532 (2008).
    • (2008) N. Engl. J. Med. , vol.359 , Issue.24 , pp. 2521-2532
    • Bejon, P.1    Lusingu, J.2    Olotu, A.3
  • 113
    • 78650253263 scopus 로고    scopus 로고
    • Immunogenicity safety and tolerability in adults of a new single-dose live-attenuated vaccine against Japanese encephalitis: Randomised controlled phase 3 trials
    • Torresi J, McCarthy K, Feroldi E, Méric C. Immunogenicity, safety and tolerability in adults of a new single-dose, live-attenuated vaccine against Japanese encephalitis: randomised controlled Phase 3 trials. Vaccine 28(50), 7993-8000 (2010).
    • (2010) Vaccine , vol.28 , Issue.50 , pp. 7993-8000
    • Torresi, J.1    McCarthy, K.2    Feroldi, E.3    Méric, C.4
  • 114
    • 78751677635 scopus 로고    scopus 로고
    • Long term immunity to live attenuated Japanese encephalitis chimeric virus vaccine: Randomized double-blind 5-year phase II study in healthy adults
    • Nasveld PE, Ebringer A, Elmes N et al. Long term immunity to live attenuated Japanese encephalitis chimeric virus vaccine: randomized, double-blind, 5-year Phase II study in healthy adults. Hum. Vaccin. 6(12), 1038-1046 (2010).
    • (2010) Hum. Vaccin. , vol.6 , Issue.12 , pp. 1038-1046
    • Nasveld, P.E.1    Ebringer, A.2    Elmes, N.3
  • 115
    • 67650492061 scopus 로고    scopus 로고
    • Effective preexposure and postexposure prophylaxis of rabies with a highly attenuated recombinant rabies virus
    • USA
    • Faber M, Li J, Kean RB, Hooper DC, Alugupalli KR, Dietzschold B. Effective preexposure and postexposure prophylaxis of rabies with a highly attenuated recombinant rabies virus. Proc. Natl Acad. Sci. USA 106(27), 11300-11305 (2009).
    • (2009) Proc. Natl Acad. Sci. , vol.106 , Issue.27 , pp. 11300-11305
    • Faber, M.1    Li, J.2    Kean, R.B.3    Hooper, D.C.4    Alugupalli, K.R.5    Dietzschold, B.6
  • 116
    • 77952322608 scopus 로고    scopus 로고
    • Inactivated yellow fever 17D vaccine: Development and nonclinical safety immunogenicity and protective activity
    • Monath TP, Lee CK, Julander JG et al. Inactivated yellow fever 17D vaccine: development and nonclinical safety, immunogenicity and protective activity. Vaccine 28(22), 3827-3840 (2010).
    • (2010) Vaccine , vol.28 , Issue.22 , pp. 3827-3840
    • Monath, T.P.1    Lee, C.K.2    Julander, J.G.3
  • 117
    • 79953785263 scopus 로고    scopus 로고
    • An inactivated cell-culture vaccine against yellow fever
    • Monath TP, Fowler E, Johnson CT et al. An inactivated cell-culture vaccine against yellow fever. N. Engl. J. Med. 364(14), 1326-1333 (2011).
    • (2011) N. Engl. J. Med. , vol.364 , Issue.14 , pp. 1326-1333
    • Monath, T.P.1    Fowler, E.2    Johnson, C.T.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.